List of Excipients in Branded Drug FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Generic Drugs Containing FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	fosinopril sodium and hydrochlorothiazide	54868-5346	ANHYDROUS LACTOSE
Physicians Total Care Inc	fosinopril sodium and hydrochlorothiazide	54868-5346	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	fosinopril sodium and hydrochlorothiazide	54868-5346	CROSPOVIDONE
Physicians Total Care Inc	fosinopril sodium and hydrochlorothiazide	54868-5346	POVIDONE
Physicians Total Care Inc	fosinopril sodium and hydrochlorothiazide	54868-5346	SODIUM STEARATE

What are the Most Frequently-Used Excipients in FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
7	ANHYDROUS LACTOSE
4	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
4	CROSPOVIDONE
3	FERRIC OXIDE RED

Fosinopril Sodium and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Fosinopril sodium/hydrochlorothiazide is a mature, multisource antihypertensive combination with limited conventional patent protection and modest branded commercial value. The main opportunities are low-cost generic manufacturing, differentiated tablet performance, supply-chain resilience, private-label distribution, and reformulation into line extensions. Excipient selection should prioritize chemical stability, tablet robustness, dissolution consistency, low manufacturing cost, and broad regulatory acceptability.

The reference product is Monopril HCT, a fixed-dose combination of the ACE inhibitor fosinopril sodium and the thiazide diuretic hydrochlorothiazide. The principal marketed strengths are 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg tablets, although availability varies by market and supplier. The product is an immediate-release oral tablet, not a biologic, complex injectable, or controlled-release dosage form.

What is the regulatory and commercial status of fosinopril sodium/hydrochlorothiazide?

Fosinopril sodium/hydrochlorothiazide is an established fixed-dose antihypertensive combination. In the United States, the product was approved under an abbreviated new drug or legacy branded-drug framework and has been marketed for decades. Its commercial profile is consistent with an older generic cardiovascular product: price competition is high, clinical differentiation is limited, and supply reliability often matters more than brand positioning.

Attribute	Assessment
Active ingredients	Fosinopril sodium and hydrochlorothiazide
Therapeutic class	ACE inhibitor plus thiazide diuretic
Dosage form	Immediate-release tablet
Reference brand	Monopril HCT
Originator	Bristol-Myers Squibb
Main strengths	10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg
Regulatory pathway for new generics	ANDA in the United States
Biologic status	Not applicable
Biosimilar pathway	Not applicable
Primary commercial competition	Generic fixed-dose combinations and separate-component therapy
Main technical risk	Fosinopril stability, content uniformity, dissolution, and moisture control
Main commercial risk	Low reimbursement and limited market growth

The combination is pharmacologically rational. Fosinopril inhibits the renin-angiotensin system, while hydrochlorothiazide increases sodium and water excretion. The two agents are often used when monotherapy does not achieve adequate blood-pressure control.

What excipients are used in the reference product?

The reference Monopril HCT formulation has historically used a conventional direct-compression or dry-granulation excipient platform. Public labeling identifies excipients including lactose, crospovidone, povidone, sodium stearyl fumarate, and colorant components such as yellow iron oxide, depending on strength and presentation.[1]

The reference excipient system is commercially important because it indicates the formulation target for generic development. An ANDA applicant does not normally need to duplicate the reference formulation quantitatively. It must demonstrate pharmaceutical equivalence, bioequivalence, acceptable quality, and compliance with applicable inactive-ingredient requirements.

Reference-product excipient functions

Excipient	Primary function	Development relevance
Lactose	Diluent and compression aid	Supports tablet mass and manufacturability
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Povidone	Binder	Improves granule or tablet cohesion
Sodium stearyl fumarate	Lubricant	Reduces sticking and ejection force
Yellow iron oxide	Colorant	Supports product identification and strength differentiation

Lactose is cost-effective and widely accepted, but it can create development issues for manufacturers seeking a lactose-free product or serving markets with strong preference for alternative fillers. Crospovidone is suitable for rapid disintegration, although its concentration and grade can affect dissolution. Povidone can improve tablet hardness but may increase moisture sensitivity if used at excessive levels.

Sodium stearyl fumarate is a useful alternative to magnesium stearate when the development team seeks lower hydrophobicity or improved dissolution robustness. Magnesium stearate is cheaper and widely available, but over-lubrication can slow wetting and dissolution.

How should an excipient strategy be designed?

The best generic formulation strategy is a low-complexity immediate-release tablet with a robust dissolution profile across normal manufacturing variation. The formulation should avoid unnecessary novel excipients because the product has no strong clinical or commercial rationale for higher development risk.

Recommended formulation architecture

A practical development platform may use:

• Lactose monohydrate or microcrystalline cellulose as the principal diluent.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Povidone or low-substituted hydroxypropyl cellulose as the binder.
• Sodium stearyl fumarate or magnesium stearate as the lubricant.
• Colloidal silicon dioxide as a glidant where needed.
• Iron oxide or another permitted colorant for strength differentiation.

The central formulation issue is balancing tablet hardness against rapid drug release. Fosinopril sodium is water soluble, while hydrochlorothiazide has lower aqueous solubility and can become the dissolution-limiting component. Excessive compression force, high lubricant concentration, or excessive hydrophobic coating can reduce hydrochlorothiazide release.

Excipient selection by development objective

Development objective	Preferred approach	Main trade-off
Lowest cost	Lactose, crospovidone, magnesium stearate	Greater sensitivity to lubrication and compression
Lactose-free product	Microcrystalline cellulose, mannitol, dibasic calcium phosphate	Higher tablet weight or different dissolution behavior
Fast disintegration	Crospovidone or croscarmellose sodium	Potential sensitivity to compression and moisture
Better flow	Colloidal silicon dioxide and engineered filler	Added process complexity
Lower sticking risk	Sodium stearyl fumarate	Higher excipient cost
Direct compression	Co-processed filler or robust microcrystalline cellulose system	May require tighter raw-material controls
Moisture control	Dry granulation, low-moisture excipients, high-barrier packaging	Higher equipment or packaging cost

What stability risks affect fosinopril sodium/hydrochlorothiazide tablets?

Fosinopril sodium contains a phosphinate-containing prodrug structure that requires controlled moisture and storage conditions. The finished product must be evaluated for degradation of fosinopril-related substances and preservation of hydrochlorothiazide assay and dissolution.

The principal formulation and packaging risks are:

1. Moisture uptake by hygroscopic or porous excipients.
2. Chemical degradation during wet granulation or high-humidity processing.
3. Dissolution drift caused by lubricant distribution or compression changes.
4. Color variation from iron oxide dispersion.
5. Impurity growth during accelerated storage.
6. Interaction between packaging permeability and tablet moisture content.

A dry process is generally more attractive than aqueous wet granulation unless laboratory data show a clear benefit from wet granulation. Dry granulation or direct compression reduces exposure to water and simplifies scale-up.

Packaging strategy

A standard high-density polyethylene bottle with a desiccant may be adequate for a robust formulation. A blister using aluminum foil or a high-barrier polymer may provide stronger moisture protection and better unit-dose presentation, but packaging cost is higher.

The commercial choice depends on the target market:

• Retail generic: bottle packaging usually offers the lowest cost.
• Institutional or hospital use: unit-dose blisters can improve dispensing efficiency.
• Hot and humid markets: high-barrier blister or bottle systems can reduce stability risk.
• E-commerce: bottle packaging may simplify logistics, while induction seals and desiccants improve shelf-life protection.

What patent protection covers fosinopril sodium/hydrochlorothiazide?

The core composition and fixed-dose combination patents for fosinopril and hydrochlorothiazide are old relative to current pharmaceutical patent terms. The product is not generally viewed as having an active, commercially meaningful composition-of-matter barrier in the United States.

The relevant protection historically included:

• Fosinopril compound patents.
• Fosinopril salt and pharmaceutical-composition claims.
• Fixed-dose combination claims involving an ACE inhibitor and hydrochlorothiazide.
• Manufacturing and formulation claims.
• Product-label or method-of-use claims for hypertension.

Those patent categories have largely matured beyond their primary exclusionary periods. Current competition is therefore more likely to depend on FDA approval timing, manufacturing economics, supply continuity, and customer contracts than on blocking patent rights.

Orange Book status

The Orange Book is the relevant FDA source for listed patents and exclusivity associated with approved small-molecule products.[2] For an old fixed-dose combination such as fosinopril sodium/hydrochlorothiazide, the expected position is:

Issue	Commercial assessment
New chemical entity exclusivity	Expired
Core composition patent	Expected expired
Fixed-dose combination patent	Expected expired or commercially nonblocking
Pediatric exclusivity	No material current relevance identified
Active formulation patent	No widely recognized blocking estate
Paragraph IV significance	Low unless a new listed patent exists for a specific product
ANDA entry barrier	Primarily technical and commercial

A current product-specific Orange Book review is required before relying on a patent conclusion for a live filing, acquisition, or litigation decision. Patent status can differ by strength, dosage form, listed product, and market.

When does fosinopril sodium/hydrochlorothiazide lose exclusivity?

The commercially important exclusivity period has already ended. Fosinopril and hydrochlorothiazide are established small molecules, and generic competition is legally possible in principle where an approved reference product and viable market remain.

The relevant timing question is not whether basic exclusivity remains. It is whether a manufacturer can obtain approval at a cost compatible with the achievable net price.

Generic launch scenarios

Scenario	Timing profile	Commercial implication
Standard ANDA with no blocking patent	Approval after complete review	Immediate price competition
ANDA with deficiency cycles	Delayed by months or longer	Higher development cost
Product requiring bioequivalence optimization	Moderate delay	Greater formulation and analytical expense
Limited-supplier market	Rapid share capture possible	Supply reliability becomes valuable
Low-volume market	Approval may be technically feasible but unattractive	Contract manufacturing or private label may be needed
New formulation or packaging	Longer development cycle	Requires a clear price or channel advantage

Are there Paragraph IV challenges or patent litigation?

Fosinopril sodium/hydrochlorothiazide is not associated with a current high-profile patent litigation landscape comparable to newer branded cardiovascular products. Paragraph IV challenges would have had their principal significance during the period when listed patents remained enforceable. For a mature combination, current litigation risk is more likely to arise from:

• ANDA applicant patent certifications.
• Manufacturing-process claims.
• Trade dress or trademark disputes.
• Supplier qualification and quality-system issues.
• Contract disputes involving private-label distribution.
• Alleged infringement of newly issued formulation claims, if any are listed.

No biosimilar litigation applies because the product is a chemically synthesized small molecule, not a biologic regulated under the Public Health Service Act.

What formulation patents could create new commercial value?

The strongest potential patent opportunities are not likely to come from the basic combination. They would need to address a genuine technical or clinical distinction.

Potentially patentable concepts include:

• Improved moisture-stable tablet compositions.
• Low-lactose or lactose-free formulations.
• Rapid-disintegration tablets with demonstrated bioequivalence.
• Taste-masked orally disintegrating dosage forms.
• Unit-dose packaging that extends stability in high-humidity environments.
• Fixed-dose combinations with modified strength ratios.
• Adherence-focused packaging or calendar blister systems.
• Process controls that reduce impurity formation.
• Novel granulation or compression methods with measurable manufacturing benefits.

A formulation patent must provide more than a routine excipient substitution. A claim directed only to replacing lactose with microcrystalline cellulose, or magnesium stearate with sodium stearyl fumarate, may face obviousness challenges unless the formulation produces an unexpected stability, dissolution, impurity, or manufacturing result.

What commercial opportunities exist for manufacturers?

The most credible opportunities are operational rather than premium-brand opportunities.

1. Reliable generic supply

Older antihypertensive combinations can experience intermittent availability when few manufacturers remain. A supplier with validated dual-source API procurement, stable packaging supply, and strong quality systems can win pharmacy, wholesaler, and institutional contracts.

2. Private-label and regional distribution

The product can fit private-label portfolios serving regional wholesalers, pharmacy groups, government tenders, and discount channels. The low unit price limits promotional spending, so distribution access and supply performance are central.

3. Differentiated packaging

High-barrier blister packs, unit-dose formats, and multilingual labeling can support institutional sales or export markets. Packaging differentiation is more defensible commercially than a minor excipient change.

4. Combination-product portfolio expansion

A manufacturer with fosinopril, hydrochlorothiazide, and other antihypertensive products can use the combination to strengthen a cardiovascular portfolio. Cross-selling separate-component products may improve procurement economics.

5. Emerging-market supply

Markets with growing hypertension prevalence may support demand, but registration requirements, price controls, local manufacturing rules, and tender economics can compress margins. A formulation using globally available excipients reduces regulatory and supply-chain risk.

How does this product compare with competing antihypertensive combinations?

Fosinopril/hydrochlorothiazide competes with more widely prescribed ACE inhibitor/thiazide and angiotensin-receptor blocker/thiazide combinations.

Combination	Competitive position
Fosinopril/HCTZ	Mature, low-cost, limited differentiation
Lisinopril/HCTZ	Broad generic availability and stronger prescription familiarity
Enalapril/HCTZ	Established ACE inhibitor combination
Losartan/HCTZ	Strong ARB-based alternative
Valsartan/HCTZ	Broad historical commercial use
Benazepril/HCTZ	Smaller but relevant ACE inhibitor segment

The main disadvantage is limited prescribing momentum compared with lisinopril/HCTZ and losartan/HCTZ. The main opportunity is lower-cost supply in markets where fosinopril remains included in treatment guidelines or procurement formularies.

How strong is the patent estate?

The patent estate is weak as a current exclusionary asset and moderate as a historical technical asset.

Patent-estate factor	Rating	Explanation
Composition-of-matter protection	Low	Mature active ingredients
Fixed-dose combination protection	Low	Old combination technology
Formulation differentiation	Low to moderate	Possible only with demonstrated technical effects
Manufacturing-process protection	Low to moderate	Potentially relevant for impurity and stability control
Regulatory exclusivity	Low	No expected current NCE barrier
Commercial defensibility	Moderate	Supply, quality, packaging, and distribution can support returns
Litigation exposure	Low	No major current patent dispute profile identified

What is the revenue exposure?

The revenue opportunity is usually modest on a per-unit basis but can be attractive at scale. Revenue depends on:

• Number of approved strengths.
• Reimbursement status.
• Wholesale acquisition price.
• Tender or contract pricing.
• Competitive supplier count.
• Stock-out frequency.
• Geographic registration footprint.
• Ability to manufacture at high yield.

The product is unlikely to support a premium price solely through excipient selection. A premium requires a measurable benefit such as improved stability, easier administration, better packaging, or a regulated product presentation that solves a customer problem.

Key Takeaways

• Fosinopril sodium/hydrochlorothiazide is a mature immediate-release generic combination.
• The reference excipient platform uses conventional ingredients, including lactose, crospovidone, povidone, sodium stearyl fumarate, and colorants.
• The preferred generic strategy is a simple, moisture-controlled tablet with rapid and consistent hydrochlorothiazide dissolution.
• Dry granulation or direct compression is generally more attractive than aqueous wet granulation for stability and scale-up.
• Core patent and regulatory exclusivity barriers are expected to have expired.
• Biosimilar risk is not applicable.
• Paragraph IV and current patent litigation risk are expected to be limited compared with newer branded drugs.
• Commercial value rests on manufacturing cost, supply reliability, packaging, private-label access, and geographic coverage.
• New formulation patents require demonstrated technical advantages, not routine excipient substitution.
• The strongest opportunity is a dependable, low-cost multisource product with validated stability and broad market registration.

FAQs

Is fosinopril sodium/hydrochlorothiazide still protected by a composition patent?

The core composition and combination technology are mature, and no commercially meaningful basic composition barrier is generally expected to remain. Product-specific Orange Book records should be checked before filing or acquisition decisions.

Can a lactose-free fosinopril/hydrochlorothiazide tablet be developed?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed fillers can replace lactose, subject to dissolution, stability, manufacturability, and inactive-ingredient requirements.

Does hydrochlorothiazide control the dissolution strategy?

Often. Fosinopril sodium is relatively water soluble, while hydrochlorothiazide can be more sensitive to compression, lubrication, particle size, and wetting conditions. The formulation should be optimized against the slower-releasing component.

Is an orally disintegrating version commercially attractive?

It could support differentiation, but the opportunity is limited unless the product demonstrates a meaningful adherence, swallowing, or convenience benefit. Taste, dose loading, moisture protection, and tablet robustness are key barriers.

Which commercial advantage is more valuable than a novel excipient?

Reliable supply is usually more valuable. Dual-source APIs, qualified excipients, strong process capability, high batch yield, and dependable regulatory maintenance can create more durable returns than a minor excipient change.

References

1. Bristol-Myers Squibb Company. (n.d.). Monopril HCT prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2014). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms. Guidance for Industry.

5. National Library of Medicine. (n.d.). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov/dailymed/